MGAT1-CD73 interaction

The "MGAT1-CD73 interaction" refers to the enzymatic modification of the immune checkpoint protein CD73 by the glycosyltransferase MGAT1. MGAT1 catalyzes the addition of N-acetylglucosamine to specific sites on CD73, promoting its dimerization and efficient translocation to the cell membrane[1][3][5]. Once on the membrane, CD73 converts AMP to immunosuppressive adenosine, which dampens anti-tumor T cell responses. Overexpression or increased activity of MGAT1 enhances this immunosuppressive pathway, facilitating tumor immune evasion. Inhibiting the MGAT1-CD73 glycosylation axis (for example, using small-molecule inhibitor W-GTF01) can reduce CD73 cell-surface expression, restore CD8+ T cell activity, and sensitize tumors to immunotherapy, particularly in immune-cold cancers[3][5]. However, as this "target" is a molecular interaction between two proteins rather than a single, well-defined receptor or enzyme, it should not be considered a conventional therapeutic target entity for standard drug discovery pipelines.

Inhibition of MGAT1-catalyzed glycosylation of CD73 prevents CD73 surface translocation and dimerization, thereby reducing adenosine-mediated immune suppression[3][5].